HFSA Annual Scientific Meeting 2021

Proposal submissions are closed at this time

IMPORTANT REMINDER: All co-authors are responsible for entering their disclosures into the HFSA Portal. During the submission process primary authors will be able to send a notification email to co-authors that have no disclosures on file. All co-author disclosures must be received by the submission deadline of May 14, 2021, 11:59 PM ET. Abstracts with incomplete disclosures will not be considered for presentation or publication. 

Abstracts on heart failure research are invited in the following categories:

• Biomarkers / Neurohormones / Cytokines
• Cardiovascular Pharmacology
• Cardiovascular Physiology
• Cardiovascular Structure / Imaging
• Clinical Care
• Clinical Trials
• Coronavirus (COVID-19)
• Electrophysiology / Arrhythmias
• Epidemiology / Prevention
• Health Disparities – NEW CATEGORY FOR 2021!
• Management Strategies / Adherence / Self Care
• Molecular Biology / Genetics / Cell Therapy
• Performance Improvement Initiatives/Case Studies*
• Quality of Care / Outcomes
• Surgery /Transplantation / Devices

*Note: Case Studies and Performance Improvement Initiative abstracts are not eligible for awards.

HFSA will be utilizing ePosters at HFSA 2021. An ePoster is a digital presentation of a poster. Attendees will be able to view ePosters designation viewing areas in the Exhibit Hall during the Annual Scientific Meeting, regardless of day and time of presentations

Accepted poster authors will receive technical guidelines on how to prepare a PDF document to display properly as an ePoster and printed poster instructions.

Presenting authors of accepted abstracts will be required to register for the meeting. Accepted posters will be designated a specific date and time for poster presentations. 

About the Awards

HFSA offers three investigator award competitions at its annual meeting. These awards are to recognize research excellence in young trainees and investigators. Finalists will present their work orally in scientific sessions during the Annual Scientific Meeting.

Award finalists will be notified in early-July. Monetary awards are provided to first place presenters and to the second-place presenter of the JNCNI award. All award finalists receive complimentary registration to the Annual Scientific Meeting.

Note: Case Studies and Performance Improvement Initiative abstracts are not eligible for awards.

Jay N. Cohn New Investigator Award – Basic Science/Clinical

Eligibility:  Candidates must have completed training no earlier than 2020, be first author, and have played a major role in research study being submitted. The finalist must present their research results in respective JNCNI award session during the 2021 HFSA Annual Scientific Meeting.

Nursing Investigator Awards

• Nursing Investigator Award – Research: This award recognizes outstanding and innovative research in the field of heart failure by a nurse researcher. A review committee will choose up to five finalists.
• Nursing Investigator Award – Clinical: This award recognizes outstanding and innovative nurses in the field of heart failure by that are active in clinical nursing research. Up to five finalists are chosen.

Eligibility: Candidates must be a nurse investigator or a student in an accredited nursing program and first author and presenter of the abstract submitted. Candidate cannot be a member of the HFSA Nursing Award Committee. Previous finalists for this award are ineligible. Individuals cannot apply for both the Clinical Excellence in Nursing and Nursing Research Awards in the same year.

Electronic Submissions

The submission site works optimally with Microsoft Internet Explorer 7, Safari version 3.2 or higher, or Mozilla Firefox version 6.0 or higher (some aspects may not work so well with Chrome). The Call for Abstracts screen provides links to this free software. The site is available 24 hours a day. Multiple authors can easily review or work on the abstract from different locations. The site supports graphic images, tables (with special characters/symbols), Greek characters and special symbols.

The 2021 HFSA Annual Scientific Meeting will feature ePosters, oral presentations, oral abstract award sessions, and a special electronic supplemental Issue of the Journal of Cardiac Failure with published abstracts.

Acceptance

1. All abstracts submitted must comply with the guidelines to be considered for acceptance.
2. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit.
3. Acceptance notifications will be sent in early July 2021.
4. Authors will be expected to attend the meeting and present their posters
5. Authors will receive technical guidelines on how to prepare a PDF document to display properly as an ePoster.
6. Abstracts accepted are embargoed (see embargo policy) for release until the time of   presentation at the Heart Failure Society of America’s Scientific Meeting.
7. Abstracts accepted for presentation will be published in an electronic supplemental issue of the Journal of Cardiac Failure. Authors whose abstracts are accepted give HFSA permission and authority to submit and publish their abstract, without compensation, in the Journal of Cardiac Failure.
8. HFSA reserves the right to all video or audio recordings of presentations at the 2021 Annual Scientific Meeting

Author’s Conflict

If the abstract is selected, author is required to present their research at the annual meeting to be published in JCF.  If they have a conflict, they can allow a co-author present in their place, but will need to notify us in advance.  Notification letters will go out in early July.  They will have approximately 2 weeks to accept or decline their invitation to present.  If decline, their abstract will not be published in JCF.

Abstracts selected for oral presentation in an award session will receive special notification letters with additional information.

To determine if an author has accepted abstract to be presented:  Click on “Notifications” on the home page in ADMIN, then click the title of the Notification that was sent to the author.  Click “Manage Expiration” and then you can locate the authors control or name or email to see if they accepted their invitation [you will need to know which abstract, because an author can submit more than one abstract].  Another way to do this is to do an abstract search using “Advanced Search.”  Click on the session title under the abstract and then locate the abstract within the session to see if they accepted the invitation.

Abstracts accepted are embargoed for release until the first day of the HFSA Annual Scientific Meeting.

The standard is that any company can announce at any time the following:

• Announcement that trial is completed
• That results will be presented at so and so date in such and such a meeting
• What did the trials assess – basic design, questions, study population, interventions etc.
• NO RESULTS AT ALL OR ANY HINT OF RESULTS INDIRECTLY
   

Author Names

If an author’s name appears on more than one abstract, it must be identical on each abstract. The submitting author is designated as the presenting or primary author – the presenting   author is shown in green in Oasis. The senior author must always be listed last.

Abstract Data

1. The Heart Failure Society of America is a forum for presentation of novel research findings. Therefore, work covered by the abstract must not have been published as a manuscript or abstract prior to March 31, 2021.
2. Abstract data may not be presented at a national meeting or world congress in the United States prior to July 1, 2021.
3. Data should not be “split” to create several abstracts from one. Splitting will result in reduced scores for related abstracts.
4. Abstracts containing identical or nearly identical data submitted from the same institution or individual will be disqualified.
5. Informed consent: any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1996;14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any procedures performed must meet with prevailing ethical standards.
6. Use of Animals: All studies involving the use of animals must conform with the 1991 revision of “Guiding Principles in the Care and Use of Animals” (American Physiological Association).

Award Competitions

If submitting for an award competition, please check the appropriate box and provide required information. Abstracts submitted for award competition cannot be submitted as Poster Presentation Only.

Co-Author Approval

The submitting author must verify that all co-authors have read and approved the abstract submission.

Disclosure Form

A disclosure form identifying commercial relationships for all co-authors must be completed online by all the authors. Each author must have a current disclosure status before May 3, 2021, 10:00 AM ET or the abstract will remain incomplete and will not be reviewed.

Disclosure information for accepted abstracts will be made available to the 2021 scientific meeting attendees.
 

Abstract Submissions by Industry

Abstract submissions from industry are allowed. Submissions must focus on science and research, not on specific products or services. Abstract presentations cannot be sales presentations or endorsements for products or services.

Abstract Withdrawal

Withdrawal of accepted abstracts must be received in writing (via email) by HFSA no later than July 30, 2021 to avoid publication in the Journal of Cardiac Failure electronic supplemental issue.

Writing an Abstract

• Title: Make the title dynamic and conclusive, rather than descriptive
• Structure: A well-written abstract typically has the following identified sections: Introduction, Hypothesis, Methods, Results and Conclusions.
• Category: Check submission category carefully to assure proper consideration.
• Length: Maximum length is 2800 characters, including tables and graphs.

Title

An abstract must have a short, specific title (no abbreviations) that clearly indicates the nature of the investigation. Make the title dynamic and conclusive, rather than descriptive.

Text

• Briefly describe the objectives of the study unless they are contained in the title. If applicable, include a brief statement of methods. State findings in sufficient detail to support conclusions.   Abstracts should not describe research in which the chemical identity or source of the reagent   is proprietary or cannot be revealed.
• Use generic names wherever possible. Use trade names only when necessary.
• Avoid beginning sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations should be   placed in parentheses after the first use of the word or phrase abbreviated.
• No references, credits or grant support should be included in the abstract.
• No identifying information about patients participating in a study or trial should be used.
• Proofread abstracts carefully to avoid errors before submission. No corrections will be allowed   or made once abstract has been submitted.

Abstract Contents

The size limit for an abstract 2,800 characters, including characters in the following: abstract title, body, authors/institutions, table(s) and image(s).